Hepion Pharmaceuticals, Inc. 8-K

What Happened
Hepion Pharmaceuticals, Inc. announced it entered into securities purchase agreements and closed a private placement on April 21, 2026, selling 17,500,000 shares of common stock at $0.04 per share for gross proceeds of $700,000. The offering was made to accredited investors in reliance on Section 4(a)(2) and/or Rule 506(b) of Regulation D; the shares are unregistered and restricted from resale absent registration or an exemption.

Key Details

• 17,500,000 shares of common stock issued at $0.04 per share.
• Gross proceeds to the company: $700,000.
• Closing date: April 21, 2026; sold in a private placement to accredited investors.
• Issuance relied on Section 4(a)(2) and/or Rule 506(b); securities are unregistered and subject to resale restrictions.

Why It Matters
The transaction provides Hepion with $700,000 in immediate cash, which can affect the company’s near-term liquidity. Issuing 17.5 million new shares dilutes existing shareholders’ ownership percentage. The securities are restricted from public resale unless registered or an exemption applies, and the filing does not specify how the company will use the proceeds. Investors should note the dilution and resale limitations when assessing the company’s capital structure and share value.